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OBJECTIVES: To conduct a cost-utility evaluation of dabigatran etexilate compared
with enoxaparin for the prevention of venous thromboembolism (VTE) after total
knee replacement (TKR) and total hip replacement (THR) in Colombia. METHODS:
An acute phase model, using decision analysis, and a long-term simulation Markov
model were developed to compare the clinical outcomes, utilities, and direct med-
ical costs of dabigatran 220 mg once daily and subcutaneous enoxaparin 40 mg
once daily for VTE prophylaxis after TKR or THR. Time frame for the acute inpa-
tient-phase was 14 days for TKR and 30 days for THR; adjustments for adverse
events and average length of hospital stay were performed. The long-term simu-
lation was performed using 6-months cycle transitions to eight health states for
both TKR and THR. Transition probabilities for VTE and bleeding events were de-
rived from Phase III studies comparing the two treatments. The probabilities of
long-term events were estimated using data from published longitudinal studies.
The payer perspective for a lifetime horizon was used. Sensitivity analyses were
performed to assess the model robustness. The annual discount rate was set at
3.0%. RESULTS: During the acute phase, for TKR, patients with dabigatran had
lower direct medical costs than enoxaparin (US$1.005,83 vs. US$1.392,25), with 0.1
difference in QALYs (0.9 vs.0.8 respectively). For THR, cost of dabigatran were
US$868.73, and US$1,007.55 for enoxaparin; no differences in QALYs were calcu-
lated. In the long-term follow-up, for both procedures, the costs associated with
dabigatran were US$115,433, compared to US$122,695 for enoxaparin, with differ-
ences in QALYs of 7.4 for dabigatran and 6.7 for enoxaparin. Life-term analyses
reported a dominance of dabigatran over enoxaparin. Results were robust across
sensitivity analyses. CONCLUSIONS: In Colombia, thromboprophylaxis with dab-
igatran was cost-saving compared with enoxaparin in patients undergoing major
joint replacement.
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OBJECTIVES: To evaluate the cost-effectiveness of prasugrel versus clopidogrel in
patients with acute coronary syndromes (ACS) undergoing percutaneous coronary
intervention (PCI) from the private healthcare payer perspective in Mexico.
METHODS: The alternatives were prasugrel (loading dose 60 mg, maintenance
dose 10 mg daily) versus clopidogrel (loading dose 300 mg, maintenance dose 75 mg
daily). A Markov model was developed. Only direct medical care costs were con-
sidered for one year. The efficacy measure was a composite of the death from
cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke, and stent
thrombosis reported in the trial directly comparing prasugrel and clopidogrel
(TRITON TIMI-38). Three types of populations were evaluated separately; overall,
patients with diabetes mellitus and the subset of diabetics treated with insulin.
Care costs were derived from medical records, and the costs of drugs were assumed
to be the same. Costs and the model were validated by experts. RESULTS: Accord-
ing to the model, patients treated with prasugrel had fewer events in the three
types of populations evaluated over a 12 month time horizon. The number of
events; death from cardiovascular causes, nonfatal myocardial infarction-stroke
and stent thrombosis avoided by 10,000 patients were distributed as follows: over-
all population, 15, 239 and 132, diabetics, 51, 667 and 175, diabetics on insulin, 87,
1041 and 496. The average cost per patient (2010 Mexican pesos) treated with pra-
sugrel was lower compared with clopidogrel, for the overall population
(MXN$106,549 vs. MXN$108,991), diabetics (MXN$114,832 vs. MXN$130,872) and
diabetics treated with insulin (MXN$121,089 vs. MXN$157,502) CONCLUSIONS: Re-
sults from the present analysis suggest that the use of prasugrel (instead of clopi-
dogrel) in patients with ACS undergoing PCI, represents a more effective strategy at
a lower cost (dominant strategy), a cost-saving alternative for institutions of pri-
vate healthcare in Mexico.
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OBJECTIVOS: La comunicación interatrial (CIA) es la segunda cardiopatía congénita
en la infancia y la tercera en el adulto. Realizamos un análisis costo-efectividad del
cierre de la CIA con Técnica Percutánea (TP) con oclusor Amplatzer septal occluter
ASOÒ vs Técnica Quirúrgica (TQ), desde la perspectiva del proveedor de servicios
de salud.METODOLOGÍAS:Mediante una cohorte prospectiva de pacientes con CIA
atendidos en un hospital de tercer nivel del Instituto de Seguridad y Servicios
Sociales de los Trabajadores del Estado (ISSSTE), se identificaron y compararon los
costos y efectividades del cierre con TP y con TQ, en ocho meses de seguimiento. La
medida de efectividad fue el éxito clínico en el cierre sin complicaciones mayores al
final del seguimiento (ECSCM). Se estimó el costo promedio por paciente y rango
intercuartílico, mediante la identificación y cuantificación de los recursos utiliza-
dos durante el seguimiento. Los costos unitarios se obtuvieron de las bases de datos
de la institución. Los costos se expresaron en pesos mexicanos del 2010. Se definió
un valor de p 0.05 como estadísticamente significativo y se utilizaron las pruebas
de U de Mann Whitney y Chi cuadrada. RESULTADOS: Entre enero de 2008 y Dici-
embre de 2009 se estudiaron 89 pacientes con CIA; Un total de 51 fueron tratados
con TQ y 38 con TP, la ECSCM con TQ fue 69% vs. 94% con TP (p0.05). El costo
promedio por paciente en el grupo de TQ fue: $137,495.16 ($108,418.10-$146,661.60)
vs. $99,850.96 ($99,746.50-$102,008.90) con TP (p0.05). El costo por paciente con
ECSCM con TQ fue $225,395.34 vs. $109,509.72 con TP. El costo-efectividad incre-
mental del tratamiento con TP vs TQ es de -$124,719.00. CONCLUSIONES: El cierre
de la CIA, en una institución de seguridad social mexicana mediante TP es costo-
ahorradora al compararse con la TQ, información que debe ser considerada por los
tomadores de decisiones.
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OBJECTIVES: To evaluate the cost-effectiveness and cost-utility of the implantable
cardioverter–defibrillator (ICD) among patients who are at risk for sudden death in
Argentina, from three insurance categories: public health, social security and
private.METHODS:We developed a Markov model to evaluate the survival, quality
of life and cost of the prophylactic implantation of an ICD, as compared with
pharmacological therapy, among three different target populations defined using
clinical trials selected through a systematic review. We measured effectiveness,
resource use and cost parameters. A healthcare system perspective was adopted
and a 3% discount rate was used. RESULTS: The use of an ICD was more costly but
more effective than control therapy. The cohort with the greatest benefits was
represented by the MADIT I study showing an incremental cost effectiveness rate
(ICER) of $8,539 (dollar 2009) for public, $9,371 for social security and $10,083 for
private sector. ICERs for MADIT II population were $17,379, $18,574 and $19,799,
respectively. The secondary prevention cohort showed the worst results with IC-
ERs of $21,016, $22,520 and $24,012. The analysis was robust to different determin-
istic and probabilistic sensitivity analyses, except for the cost of ICD and for battery
life. CONCLUSIONS: The results varied considerably depending on the cohort and
discretely according to the health system. ICD could be cost-effective in Argentina,
mainly in the MADIT I patients.
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